Management of metastatic prostate cancer has undergone a revolution over the past decade
with the introduction of several novel agents and repurposing of others. Several clinical trials …

Current diagnostic tools for prostate cancer (PCa) diagnosis and risk stratification are
insufficient. The hidden onset and poor efficacy of traditional therapies against metastatic …

Prostate cancer is generally considered an immunologically “cold” tumor type that is
insensitive to immunotherapy. Targeting surface antigens on tumors through cellular therapy …

Abstract Background Traditional Chinese Medicine (TCM) CFF-1 has been used in clinic for
prostate cancer therapy in China. We reported before CFF-1 induced cell apoptosis via …

Prostate cancer remains the second most common malignancy in men worldwide, is a
global health issue, and poses a huge health burden. Precision medicine provides more …

Chronic wounds impose a significant healthcare burden to a broad patient population. Cell-
based therapies, while having shown benefits for the treatment of chronic wounds, have not …

Prostate cancer ranks as the second most common malignancy in males. Prostate cancer
progressing on androgen deprivation therapy (ADT) is castration-resistant prostate cancer …

Twenty new compounds, targeting CYP17A1, were synthesized, based on our previous
work on a benzimidazole scaffold, and their biological activity evaluated. Inhibition of …

Globally, prostate cancer (PCa) is one of the most common cancers to strike men. Diet and
lifestyle appear to have a significant impact on PCa biology and carcinogenesis. PCa is the …

Prostate cancer (PCa) affects males of all racial and ethnic groups, and leads to higher rates
of mortality in those belonging to a lower socioeconomic status due to the late detection of …